Tiarnan D L Keenan1, Raph Goldacre2, Michael J Goldacre2. 1. Centre for Hearing and Vision Research, Institute of Human Development, University of Manchester, Manchester, England. 2. Unit of Health-Care Epidemiology, Department of Public Health, University of Oxford, Oxford, England.
Abstract
IMPORTANCE: The potential association between age-related macular degeneration (AMD) and Alzheimer disease (AD) is uncertain and has implications for understanding disease pathogenesis, referral, and treatments. OBJECTIVES: To determine whether individuals admitted to the hospital with AMD were significantly more or less likely to develop AD or dementia in the following years, as well as to assess whether people with AD or dementia were significantly more or less likely to be admitted to the hospital for AMD treatment in the years following diagnosis of dementia. DESIGN, SETTING, AND PARTICIPANTS: An AMD cohort of 65,894 people was constructed from English National Health Service, linked hospital episode statistics from January 1, 1999, through February 28, 2011, by identifying computerized record abstracts for all people with an admission or day case care for AMD. A dementia cohort (168,092 people) and a reference cohort (>7.7 million people) were constructed in similar ways. MAIN OUTCOMES AND MEASURES: Risk of AD or dementia following AMD and risk of AMD following AD or dementia. Rate ratios were calculated based on standardized rates of AD and dementia in the AMD cohort, as well as standardized rates of AMD in the AD and dementia cohort, relative to those in the reference cohort. RESULTS The risk of AD or dementia following AMD was not elevated. The rate ratio was 0.86 (95% CI, 0.67-1.08) for AD and 0.91 (0.79-1.04) for dementia. The likelihood of being admitted for AMD following AD or dementia was very low: the rate ratio was 0.04 (0.01-0.10) for people with AD and 0.07 (0.04-0.11) for those with dementia. CONCLUSIONS AND RELEVANCE: These neurodegenerative conditions may share environmental risk factors and histopathologic features. However, considering AD and other dementia after AMD, their coexistence at the individual level is no different from that expected by chance. Our data also suggest that patients in England with dementia may be substantially less likely to receive AMD treatment. Further research is required to determine whether people with dementia receive appropriate investigation and treatment for AMD, as well as identify and address potential barriers.
IMPORTANCE: The potential association between age-related macular degeneration (AMD) and Alzheimer disease (AD) is uncertain and has implications for understanding disease pathogenesis, referral, and treatments. OBJECTIVES: To determine whether individuals admitted to the hospital with AMD were significantly more or less likely to develop AD or dementia in the following years, as well as to assess whether people with AD or dementia were significantly more or less likely to be admitted to the hospital for AMD treatment in the years following diagnosis of dementia. DESIGN, SETTING, AND PARTICIPANTS: An AMD cohort of 65,894 people was constructed from English National Health Service, linked hospital episode statistics from January 1, 1999, through February 28, 2011, by identifying computerized record abstracts for all people with an admission or day case care for AMD. A dementia cohort (168,092 people) and a reference cohort (>7.7 million people) were constructed in similar ways. MAIN OUTCOMES AND MEASURES: Risk of AD or dementia following AMD and risk of AMD following AD or dementia. Rate ratios were calculated based on standardized rates of AD and dementia in the AMD cohort, as well as standardized rates of AMD in the AD and dementia cohort, relative to those in the reference cohort. RESULTS The risk of AD or dementia following AMD was not elevated. The rate ratio was 0.86 (95% CI, 0.67-1.08) for AD and 0.91 (0.79-1.04) for dementia. The likelihood of being admitted for AMD following AD or dementia was very low: the rate ratio was 0.04 (0.01-0.10) for people with AD and 0.07 (0.04-0.11) for those with dementia. CONCLUSIONS AND RELEVANCE: These neurodegenerative conditions may share environmental risk factors and histopathologic features. However, considering AD and other dementia after AMD, their coexistence at the individual level is no different from that expected by chance. Our data also suggest that patients in England with dementia may be substantially less likely to receive AMD treatment. Further research is required to determine whether people with dementia receive appropriate investigation and treatment for AMD, as well as identify and address potential barriers.
Authors: Cecilia S Lee; Eric B Larson; Laura E Gibbons; Caitlin S Latimer; Shannon E Rose; Leanne L Hellstern; C Dirk Keene; Paul K Crane Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang Journal: Alzheimers Dement Date: 2014-07-09 Impact factor: 21.566
Authors: Michael E Ward; Jeffrey M Gelfand; Li-Yung Lui; Yvonne Ou; Ari J Green; Katie Stone; Kathryn L Pedula; Steven R Cummings; Kristine Yaffe Journal: Ann Neurol Date: 2018-04-11 Impact factor: 10.422
Authors: Christopher R Carpenter; Frances McFarland; Michael Avidan; Miles Berger; Sharon K Inouye; Jason Karlawish; Frank R Lin; Edward Marcantonio; John C Morris; David B Reuben; Raj C Shah; Heather E Whitson; Sanjay Asthana; Joe Verghese Journal: J Am Geriatr Soc Date: 2019-08-22 Impact factor: 5.562
Authors: Jimmy T Le; Elvira Agrón; Tiarnan D L Keenan; Traci E Clemons; Willa D Brenowitz; Kristine Yaffe; Emily Y Chew Journal: Alzheimers Dement Date: 2021-11-10 Impact factor: 16.655
Authors: Margaret M DeAngelis; Leah A Owen; Margaux A Morrison; Denise J Morgan; Mingyao Li; Akbar Shakoor; Albert Vitale; Sudha Iyengar; Dwight Stambolian; Ivana K Kim; Lindsay A Farrer Journal: Hum Mol Genet Date: 2017-08-01 Impact factor: 6.150